Key barriers include misdiagnosis, insufficient gMG knowledge among healthcare providers, and limited access to specialists, ...

Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have myasthenia gravis throughout their journey. Bhavaraju-Sanka is the John H.

The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or ...

In a retrospective analysis, investigators in Finland studied the risk factors for intensive care unit (ICU) admission among patients with MG. Patients with MG who needed intensive care tended to be ...

Patients who have myasthenia gravis (MG) are more likely to have a severe form of the disease and more difficulty achieving remission if they are seropositive for antibodies to muscle-specific kinase ...

Please provide your email address to receive an email when new articles are posted on . Nearly half of individuals in a study about activities of daily living among more than 1,000 patients with ...

Energy, exercise, family time and even a job—those are the real-life costs of myasthenia gravis (MG) highlighted in Argenx’s new docuseries about the autoimmune disorder. The three films focus on ...

In recent years, five other drugs have been approved to treat gMG, including three complement inhibitors -- eculizumab ...

For several decades, thymectomy has been an option for the treatment of myasthenia gravis, a rare, long-term, autoimmune neuromuscular disease. This randomized clinical trial, carried out in 67 ...

Please provide your email address to receive an email when new articles are posted on . Efgartigimod, a human IgG1 antibody designed to decrease pathogenic IgG autoantibody levels, demonstrated ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...